Dr. Paz-Ares Discusses Pemetrexed Clinical Trial

Luis Paz-Ares, MD, PhD

Published Online: Monday, June 13, 2011

Print

Email

Luis Paz-Ares, MD, PhD, chair of Oncology at Seville University Hospital in Spain, discusses the pemetrexed advanced nonsquamous non–small cell lung cancer clinical trial.

View more videos of Luis Paz-Ares, MD, PhD.

Comment(s)

Your comments are valuable to us. Thank you.

Sorry, you must be logged in and registered to post a comment.

Related Articles

Maintenance Therapy With Bevacizumab/Pemetrexed Appears Superior to Bevacizumab Alone

Maintenance therapy with bevacizumab plus pemetrexed achieved a 4-month benefit in progression-free survival (PFS) versus bevacizumab maintenance therapy alone.

MetMAb Plus Erlotinib Improves Survival for Patients With MET-Positive NSCLC

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

New Crizotinib Results Show Positive Outcomes

Crizotinib demonstrated marked antitumor activity among patients with advanced ALK-positive non–small cell lung cancer.

Bringing the Oncology Community Together

Dr. Paz-Ares Discusses Pemetrexed Clinical Trial